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GABAB receptorBaclofen, a GABAB agonist, reduces ethanol intake in animals and humans, but the contrary or no effect was
also reported. Our previous study demonstrated that mice characterized as “loss of control over ethanol in-
take” had different Gabbr1 and Gabbr2 transcription levels, which express, respectively, the GABAB1 and
GABAB2 subunits in brain areas related to addictive behavior. In the present study, we tested baclofen on eth-
anol intake in mice exposed to the free-choice paradigm. Adult male Swiss mice, individually housed, had
free access to three bottles: ethanol (5% and 10%) and water. The protocol had four phases: acquisition
(AC, 10 weeks), withdrawal (W, 4 cycles during 2 weeks of 2 day-free-choice and 2 day-only-water),
reexposure (RE, 2 weeks), and adulteration of ethanol solutions with quinine (AD, 2 weeks). Mice character-
ized as “loss of control” (A, n=11, preference for ethanol in AC and maintenance of ethanol intake levels in
AD), heavy (H, n=11, preference for ethanol in AC and reduction of ethanol intake levels in AD), and light (L,
n=16, preference for water in all phases) drinkers were randomly distributed into two subgroups receiving
either intraperitoneal injections of all doses of baclofen (1.25, 2.5, and 5.0 mg/kg, given each dose twice in
consecutive days) or saline, being exposed to free‐choice. Fluid consumption was measured 24 h later. Bac-
lofen reduced ethanol intake in group L. In group H a reduction compared to AC was observed. Group A
maintained their high ethanol intake even after baclofen treatment. Activation of the GABAB receptor de-
pends on the precise balance between the GABAB1 and GABAB2 subunits, so the disproportionate transcrip-
tion levels, we reported in group A, could explain this lack of response to baclofen. These data highlight
the importance to test baclofen in individuals with different ethanol drinking proﬁles, including humans.© 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
The modulatory role of the γ-aminobutyric acid (GABA) system,
mainly GABAB receptors, has recently been related to addiction.
Numerous observations indicate that the tonic activation of GABAB re-
ceptors abolishes the reinforcement effects of morphine, cocaine, and
ethanol (Brebner et al., 2002; Filip et al., 2007; Maccioni et al., 2008).
However, selective antagonists of these receptors did not alter the
dose range of intravenously self-administered cocaine (Filip et al.,
2007) or the expression of morphine-induced place preference (Tsuji
et al., 1996). The role of increased dopamine in the nucleus accumbens
in rewarding and locomotor effects of several drugs of abuse are well
established (Koob and Bloom, 1988). Some evidence suggests the
involvement of GABAB receptor in controlling dopamine efﬂux in the
nucleus accumbens: the systemic administration of baclofen, a selective
GABAB receptor agonist, decreased nucleus accumbens dopamine efﬂux
in rats trained to self-administer amphetamine (Brebner et al., 2005) by0 Curitiba, PR, Brazil. Tel.: +55
erda).
vier OA license.a mechanism involving the stimulation of GABAB receptors located on
cell bodies in ventral tegmental area (VTA) dopamine neurons that
project to the nucleus accumbens (Liang et al., 2000).
Numerous preclinical and clinical studies have demonstrated
that GABAB receptor agonists suppress ethanol-related behaviors
(Addolorato et al., 2000, 2002; Bechtholt and Cunningham, 2005;
Colombo et al., 2000, 2002, 2003a, 2003b; Knapp et al., 2007;
Heilig and Egli, 2006; Maccioni et al., 2005, 2008; Moore and
Boehm, 2009; Walker and Koob, 2007). For example, in rats, baclofen
inhibited the acquisition of ethanol consumption and the ethanol-
induced conditioned place preference, decreased ethanol-inducedmoti-
vational properties and withdrawal symptoms (such as anxiety-related
behaviors), promoted abstinence, increased ethanol intake in a
drinking-in-the-dark procedure, and reduced ethanol consumption in
Sardinian ethanol-preferring rats. Although most data have shown that
baclofen suppresses ethanol consumption, few studies in animals have
reported that speciﬁc doses of baclofen increased ethanol self-
administration (Czachowski et al., 2006; Petry, 1997) and ethanol intake
(Smith et al., 1992, 1999). Although ethanol consumptionwas increased
in C57BL/6J mice after repeated baclofen administration in the drinking-
in-the-dark procedure (Moore et al., 2007), when microinjection of
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duced binge-like ethanol intakewas observed in the same strain (Moore
and Boehm, 2009). In humans, a recent clinical study reported no effect
of baclofen treatment on ethanol consumption (Garbutt et al., 2010), al-
though recently Muzyk et al. (2012) reported that patients treated with
baclofen experienced higher rates of abstinence and lower anxiety
scores.
Our previous study showed that the genes that encode the
GABAB1 and GABAB2 subunits (Gabbr1 and Gabbr2, respectively)
were differentially expressed only inmice that continued consuming
ethanol in large quantities even when adding quinine to ethanol
solutions (named here as “loss of control” mice or group A) using
this same three-bottle free-choice paradigm (Ribeiro et al., 2010,
2012). Only mice classiﬁed as group A showed increased Gabbr1
and Gabbr2 transcription levels in cerebral areas proposed to be
related to drug taking and drug seeking (Kalivas and Volkow, 2005;
Everitt and Robbins, 2005) suggesting that these genes may be relat-
ed to ethanol addiction.
Considering that (i) GABAB receptors appear to be involved in
ethanol related behaviors, (ii) some discrepancies have been reported
in the literature concerning the relationship between GABAB receptors
and ethanol consumption, (iii) differences in Gabbr1 and Gabbr2 tran-
scription levelswere found inmicewith different ethanol intake pheno-
types, and (iv) our validated ethanol consumption model provides an
alternative approach to the study of addictive behaviors, the present
study investigated the effect of baclofen treatment on ethanol con-
sumption in mice with different intake proﬁles.
2. Material and methods
2.1. Animals
Seventy locally bred, naive, male Swiss mice weighing 20–30 g and
aged 45 days at the beginning of the experimentwere housed individual-
ly in cages measuring 20×30×20 cm in a temperature-controlled room
(22±2 °C) maintained on a 12 h/12 h light/dark cycle (lights on at
0700 h). Food was available ad libitum (Purina Laboratories, Brazil). The
animals were weighed weekly. The experiment began after a 1-week ac-
climation period. All animalmaintenance, care, and treatment procedures
were controlled and approved by the Ethics Committee for Animal Exper-
imentation of the Setor de Ciências Biológicas, Universidade Federal do
Paraná (process no. 23075.105451/2009-19; approved November 10,
2009).
2.2. Drugs
Ethanol solutions (10% and 5%, v/v) were prepared for oral adminis-
tration by diluting ethanol P.A. (Vetec Laboratories, Bronx, NY, USA)
with tapwater every other day (to control for ethanol evaporation). Adul-
terated ethanol solutionswere preparedwith 0.005 g/L of quinine hydro-
chloride. Baclofen hydrochloride solutions (RBI, Natick, MA, USA) were
prepared for intraperitoneal administration by diluting with saline
(0.1 mL/10 g).
2.3. Experimental design
2.3.1. Extended chronic ethanol intake
A group of mice (n=60) had 24 h access to three bottles
(inverted 25 mL graduated cylinder with sipper tube) containing
10% and 5% (v/v) ethanol and tap water for 10 weeks (acquisition
phase, AC). Over the next 2 weeks, mice were submitted to four
cycles of ethanol withdrawal (withdrawal phase, W), consisting
each cycle of 2 days with access to water (W1, W2, W3 and W4)
followed by 2-day free access to ethanol solutions and water (aW1,
aW2 and aW3). For the following 2 weeks, they again had free access
to the ethanol solutions and water (reexposure phase, RE). At theend of this period, the ethanol solutions were adulterated with qui-
nine and offered to the animals for a further 2-week period (adulter-
ation phase, AD). The quinine concentration (0.005 g/L) was chosen
based on dose–response curve data previously performed in our lab
(Fachin-Scheit et al., 2006) and recently conﬁrmed by us (data not
shown here). The analysis of the dose–response curves showed
that 0.005 g/L reduced signiﬁcantly the water intake when quinine
was added without causing a total inhibition of intake, while higher
concentrations (0.01 and 0.05 g/L) caused totally inhibition, i.e. a
ceiling effect The positions of the bottles were changed on alternate
days when the ﬂuid intake was measured volumetrically. A separate
group of ethanol naive control animals (n=10) only had access to
water. At the end of the exposition to the 3-bottle free choice para-
digm, the mice were classiﬁed into groups based on their individual
patterns of ethanol preference and consumption. Firstly, we evaluat-
ed the preference between total ethanol intake (mL) and water con-
sumption during each phase for each mouse. Those mice preferring
water during all phases were classiﬁed as “light-drinker” (group L).
Those mice preferring ethanol during AC were, then, evaluated
regarding their individual ethanol consumption (g/kg/day) along
the phases: those ones maintaining [i.e., no signiﬁcant decrease]
the ethanol intake when ethanol solutions were added quinine (AD
phase) were classiﬁed as “loss of control” (group A); and those
ones with decreased ethanol consumption during the AD phase com-
pared to AC phase were classiﬁed as “heavy-drinker” (group H). The
animals that did not conform strictly to any of these patterns were
excluded from subsequent analyses.
2.3.2. Baclofen treatment
Firstly, we assessed the effect of baclofen on the ambulation in
open ﬁeld test in the dose range of 0.6–10.0 mg/kg (dose–response
curve). Naïve male Swiss mice (15/dose) received acutely i.p. injec-
tions of baclofen (0.6; 1.25; 2.5; 5.0 or 10.0 mg/kg) or saline 30 min
before their exposition to the open ﬁeld test accordingly to the
methodology described by Boerngen-Lacerda and Souza-Formigoni
(2000). Each animal was placed in the center of the arena and its am-
bulation in the central area and in the peripheral area (number of
squares invaded) was recorded for 5 min. From the obtained curve
we chose the three doses used to treat the classiﬁed groups.
After the last day of the AD phase, the animals spent 4 days in
abstinence, with access only to water. After the classiﬁcation of
mice, they were randomly distributed to receive either: (I) baclofen
(each animal received i.p. injections of all doses of baclofen:
B1.25=1.25 mg/kg, B2.5=2.5 mg/kg, B5.0=5.0 mg/kg) or (II) saline
(SAL; each animal received i.p. saline injections during the period
of baclofen treatment). Each animal assigned to the baclofen treat-
ment (I) received all baclofen doses administered using a Latin
square design. Each dose was administered twice on 2 consecutive
days, andmice had free access to ethanol andwater. Between the ad-
ministrations of the different doses, an interval of 4 days was given,
during which the animals had access only to water. The saline-
treated mice (II) were subjected to the same conditions and the
same experimental design as the baclofen-treated groups, except
the baclofen treatment. Access to the solutions of ethanol and
water (free-choice) was allowed 30 min after the injection of baclo-
fen or saline. Ethanol and water consumption was then quantiﬁed
after 24 h of the injection. The 10 animals from the ethanol naive
control group were randomly distributed into two groups designat-
ed to receive the same doses of baclofen and then to have access
only to water (III) or to 3-bottle free choice (IV). The procedure
(I) was designed to assess the baclofen effect on ethanol intake in each
different intake-proﬁle group; the procedure (II) to assess the saline
effect on ethanol intake in each different intake-proﬁle group; the
procedure (III) to assess the baclofen effect on water intake in a con-
trol group and the procedure (IV) to assess the baclofen effect on ini-
tial ethanol intake in a control group.
Fig. 1. Examples of each consumption proﬁle. Individual examples of mice that
exhibited differential patterns of ethanol consumption, expressed as a daily ﬂuid intake
average (mL). (A) A mouse from group A whose pattern indicates some degree of loss
of control over ethanol ingestion, in which ethanol intake and preference are high
throughout the acquisition phase, further increase after the withdrawal phase, and
show no reduction when the drug is made less palatable through the addition of qui-
nine (adulteration phase). (B) A mouse from group H which shows preference for eth-
anol throughout most of the weeks tested. The mouse, however, reduces ethanol intake
and preference when ethanol solutions are adulterated with quinine. (C) A mouse from
group L which exhibits preference for water over ethanol during all phases. Indeed,
ethanol intake and preference remain low, regardless of the cycle of exposure, with-
drawal, and reexposure to the drug.
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Datawere analyzed for distribution normality using the Kolmogorov–
Smirnov test and homogeneity of variance using Levene's test. Body
weight in grams and ethanol intake in milliliters were used to compute
the grams of ethanol intake per kilogram of body weight (g/kg). Ethanol
and water consumption were expressed as the daily median and lower
and upper quartiles. To classify each mouse accordingly to its ethanol
intake pattern we considered the individual preference between total
ethanol intake (mL) and water intake and also, the individual ethanol
consumption in g/kg/day in each phase: ﬁrstly, the preference between
water and total ethanol intake (mL) in each phase was detected through
Mann–Whitney test for each mouse, then, a Friedman analysis with
repeated measures followed by the multiple comparison test for each
animal to compare individual consumption throughout the phases by
considering the daily consumption for each phase (i.e., 20 measures in
the AC phase, 9 measures in the RE phase, and 10 measures in the AD
phase). After the classiﬁcation of mice into three groups (A, H, and L),
theKruskal–Wallis and Friedman analyses followed by themultiple com-
parison test were used to compare, respectively, the groups and phases
for ethanol consumption. Additionally, the Kruskal–Wallis test followed
by the multiple comparison test was used to compare groups and baclo-
fen doses for ethanol consumption during the baclofen treatment period.
All analyses were performed using Statistica 6.1 software (StatSoft,
Sao Caetano do Sul, Brazil). Differences were considered signiﬁcant
at p≤0.05.
3. Results
3.1. Extended chronic ethanol intake
3.1.1. Group classiﬁcation based on individual consumption
The analysis of the individual patterns of ethanol consumption in
the different phases and the use of the criteria established in the
Methods above enabled the classiﬁcation of the mice into three
groups: group A (n=11), group H (n=11), and group L (n=16). Ad-
ditionally, three mice died and nineteen did not conform to the
criteria for classiﬁcation. Therefore, these mice were excluded from
the subsequent analyses (for a more detailed description of the clas-
siﬁcation procedure, see our previous validation study in Fachin-
Scheit et al., 2006). For illustration, examples of each consumption
proﬁle are shown in Fig. 1, A: “loss of control” mouse; B: “heavy-
drinker” mouse; C: “light-drinker” mouse.
3.1.2. Intergroup consumption analysis
In Fig. 2 the ethanol consumption during each phase and cycle (AC,
aW1, aW2, aW3, RE and AD phases) for each group can be seen. The
Friedman analysis of variance (ANOVA) performed for ethanol consump-
tion in each group revealed a statistically reliable main effect of phase in
group A (χ2(5, 11)=38.90, pb0.001); in group H (χ2(5, 11)=48.97,
pb0.001) and in group L (χ2(5, 16)=75.52, pb0.001). The multiple com-
parison analysis showed that group A maintained the same pattern of
ethanol consumption during the AC and AD phases (p>0.05), whereas
groups H and L decreased their ethanol consumption in the AD phase
compared with the AC phase (pb0.001 and pb0.01, respectively). After
the ﬁrst withdrawal phase cycle (aW1), groups A and H maintained the
same pattern of ethanol consumption as the AC phase (p>0.05), whereas
group L increased its consumption (pb0.001). After the second and third
withdrawal cycles (aW2 and aW3) and in the RE phase, all groups
showed increased ethanol consumption compared with the AC phase
(pb0.001). Increased ethanol consumption was also observed after the
second withdrawal cycle (aW2) compared with the other two cycles
(aW3 and aW1) in all groups (pb0.001).
The Kruskal–Wallis ANOVA performed for ethanol consumption in
each phase revealed a statistically reliable main effect of group (AC:
H2, 39=27.72, pb0.001; aW1: H2, 39=21.18, pb0.001; aW2: H2, 39=7.59, pb0.03; aW3: H2, 39=22.38, pb0.001; RE: H2, 39=14.15,
pb0.001; AD: H2, 39=30.05, pb0.001). Themultiple comparison anal-
ysis showed that groups A andH consumedmore ethanol than group L
in the AC phase (pb0.001), aW1 cycle (pb0.01 and pb0.05, respec-
tively), aW3 cycle (pb0.001 and pb0.005, respectively), RE phase
(pb0.02 and p=0.06, respectively), and AD phase (pb0.001 and
Fig. 2. Total ethanol intake over 24 h during the free choice model and the baclofen
treatment. Data are expressed as median±interquartile range of ethanol intake
(g/kg/day). Ethanol consumption in the groups A, H and L during each experimental
phase prior to baclofen treatment (AC, acquisition phase; aW1, after the ﬁrst cycle of
withdrawal phase; aW2, after the second cycle of withdrawal phase; aW3, after the
third cycle of withdrawal phase; RE, reexposure phase; AD, adulteration phase).
The vertical arrows represent the beginning of the periodmicewere treated with i.p. bac-
lofen (B1.25, B2.5 and B5.0 are the doses of baclofen in mg/kg) or saline (SAL). During
this period the half of the mice that were exposed only to water during the free-choice
procedure (ethanol-naive control group) received also the three doses of baclofen and
then, had free-choice between water and ethanol solutions in home-cage. The other
half of the control group also received baclofen treatment but had only water in their
home-cage (upper right inset). In this part of the ﬁgure, WW represents the median
water consumption during all intervals between the ethanol withdrawal cycles when
only water was available. The letters or numbers over the bars represent signiﬁcant dif-
ferences (L, from group L; H, from group H; AC, from acquisition phase; S, from the
same group under saline (SAL) treatment; 2, from the 2.5 mg/kg of baclofen; 3, from
the 5.0 mg/kg of baclofen; pb0.05 at least; Kruskal–Wallis or Friedman tests followed
by multiple comparison test).
Fig. 3. Ambulation in open ﬁeld test — the bars represent the means±standard errors
of the ambulation in the central area (white) and in the peripheral area (gray) in mice
exposed to the open ﬁeld for 5 min. Each dose of baclofen (0.6; 1.25; 2.5; 5.0 and
10.0 mg/kg i.p.) or saline was administered 30 min before the test (n=15 mice/
dose). The letters above the bars represent signiﬁcant differences: S from the saline-
treated mice; B0.6 from the 0.6 mg/kg baclofen-treated mice; B1.25 from the
1.25 mg/kg baclofen-treated mice; B2.5 from the 2.5 mg/kg baclofen-treated mice
(ANOVA followed by Newman Keuls test, pb0.05).
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group L in aW2 cycle (pb0.01) and more than group H in the AD
phase (pb0.05).
3.2. Baclofen treatment
3.2.1. Baclofen effect on ambulation in open ﬁeld test (dose–response
curve)
Fig. 3 shows the effect of acutely baclofen treatment on ambulation
in open ﬁeld test. The one way ANOVA analysis followed by Newman
Keuls test revealed that the two higher doses (5.0 and 10.0 mg/kg) re-
duced signiﬁcantly the ambulation in the central area (F(5, 52)=4.27,
pb0.003) and in the peripheral area (F(5, 52)=12.40, pb0.0001)
suggesting a depressant effect in locomotion.
3.2.2. Ethanol consumption after baclofen administration
Fig. 2 also shows the effect of baclofen treatment on ethanol
consumption in the different groups. The Kruskal–Wallis analysis
followed by the multiple comparison test for each group considering
the three doses of baclofen and the saline-treated mice revealed that
1.25 mg/kg baclofen reduced signiﬁcantly the ethanol intake in the
group L (H3, 114=7.45, pb0.05) compared with the saline-treated ani-
mals. The decrease in ethanol consumption in Group H did not reach sta-
tistical signiﬁcance (H3, 78=4.44, p>0.05) and the group A maintained
its ethanol intake under all doses of baclofen treatment (H3, 76=1.64,
p>0.05). Baclofen had no signiﬁcant effect on ethanol consumption in
the control group when the three doses were compared using the
Friedman analysis (χ2(2, 4)=3.50, p=0.17).
Other Kruskal–Wallis analysis followed by multiple comparison
test was performed to compare the three groups in each phase of
the model and after each dose of baclofen treatment. The analysis rev-
ealed that group A had always higher ethanol intake compared to thegroup L. Group H also had increased ethanol intake compared to
group L during the phases of the model but when under baclofen
treatment group H and L consumed ethanol equally (AC: H2, 39=
27.72, pb0.001; aW1: H2, 39=21.18, pb0.001; aW2: H2, 39=7.59,
pb0.03; aW3: H2, 39=22.38, pb0.001; RE: H2, 39=14.15, pb0.001;
AD: H2, 39=30.05, pb0.001; SAL: H2, 160=24.79, pb0.001; B1.25:
H2, 36=10.90, pb0.005; B2.5: H2, 36=6.09, pb0.05; B5.0: H2, 36=
4.74, p=0.09).
The Friedman analysis for each group considering the ethanol in-
take during the AC, RE and AD phases and the period under the
three doses of baclofen treatment revealed signiﬁcant effect for
groups H (χ2(5, 5)=20.09, pb0.001) and L (χ2(5, 7)=16.39,
pb0.006) but no signiﬁcance for group A (χ2(5, 6)=8.00, p>0.05).
The multiple comparison test revealed that for the group H, the
three doses reduced consumption compared to RE, the two higher
doses increased intake compared to AD and the lower dose reduced
consumption compared to AC and to the 2.5 mg/kg dose. For the
group L, the two lower doses reduced intake compared to RE and
the lower dose reduced intake compared to 2.5 mg/kg dose. For
group A, a high ethanol intake was maintained during all phases
and under baclofen treatment.
When we considered the three groups with saline treatment
(nearly half of each group), we found that groups A and H returned
to their ethanol intake patterns exhibited in the AC phase, but
group L increased its ethanol consumption, suggesting an “alcohol
deprivation effect” (ADE) (H2, 160=24.79 pb0.001).
Moreover, no difference was detected in ethanol consumption in
the AC and AD phases when each baclofen-treated group was com-
pared with each respective saline-treated group, suggesting that the
random distribution of the mice to these two subgroups guaranteed
homogeneity (Mann–Whitney test, p>0.05).3.2.3. Water consumption during 24 h period after baclofen administration
We also evaluated water consumption after baclofen treatment to
verify whether its effect would be related to ﬂuid consumption in
general. The upper depicted graphic in Fig. 2 shows that the control
group maintained their water intake along the phases and during
the baclofen treatment. (χ2(11, 5)=4.12, p=0.66).
237G.R. Villas Boas et al. / Pharmacology, Biochemistry and Behavior 102 (2012) 233–2403.2.4. Body weight along the experiment
We evaluated the body weight of the different groups every week
during all the experiment to calculate ethanol consumption in g/kg/day.
ANOVA revealed no signiﬁcant difference among the groups. Aiming to
show thatmice did not present differences in bodyweight among the dif-
ferent groups over the experiment, here we show the means and
standard errors presented in the ﬁrst week of the AC (group A: 31.5±
1.0; group H: 30.6±0.8; group L: 31.9±0.7; group control: 30.1±1.2;
F3, 58=0.72 p=0.54), in the 16th week — last day of the AD phase
(group A: 39.5±1.6; groupH: 39.1±1.1; group L: 42.0±1.1; group con-
trol: 39.7±1.4; F(3, 58)=1.25 p=0.30) and in the 20thweek— last day
of baclofen-treatment period (group A: 40.9±1.2; group H: 40.1±1.3;
group L: 43.8±1.1; group control: 40.4±1.0; F(3, 56)=2.29 p=0.09).
4. Discussion
The main ﬁnding of the present study was the demonstration of
the differential effects of baclofen on ethanol consumption depending
on intake proﬁle in mice. Mice characterized as “loss of control”
maintained their high ethanol intake under baclofen treatment. How-
ever, the lowest dose of baclofen reduced ethanol intake in “light-
drinkers”. This same dose of baclofen also reduced ethanol intake in
“heavy-drinkers” but only in relation to their own consumption in
AC phase. As described earlier in the Introduction section, some
inconsistencies are found regarding the baclofen effect on ethanol
intake (Bechtholt and Cunningham, 2005; Colombo et al., 2000,
2002, 2003a, 2003b; Knapp et al., 2007; Maccioni et al., 2005, 2008;
Moore and Boehm, 2009; Walker and Koob, 2007; Czachowski et al.,
2006; Petry, 1997; Smith et al., 1992, 1999; Moore et al., 2007).
These discrepancies might be due to individual variability demon-
strated here by the individual intake proﬁle or due to different spe-
cies, administration routes, procedures and doses of baclofen used.
Here, we raised the hypothesis that ethanol consumption observed
in the present study, which are phenotypic manifestation, may have
been related to genotypic differences among groups. This is because
our previous study using the same paradigm (Ribeiro et al., 2010,
2012) demonstrated that the genes that encode the GABAB1 and
GABAB2 subunits were differentially expressed in mice that exhibited
a “loss of control” proﬁle just in brain areas which have been proposed
bymany authors (Kalivas andVolkow, 2005; Everitt and Robbins, 2005)
to be related to addictive behavior. Ribeiro et al. (2010, 2012) demon-
strated that animals from group A compared to the other two groups:
had higher Gabbr1 and Gabbr2 transcription levels in the prefrontal cor-
tex; lower Gabbr2mRNA levels in the hippocampus and higher Gabbr1
transcription levels in the striatum. How these differences in transcrip-
tion levels may account for differences in ethanol consumption is still
unknown. Indeed, this was the main reason why we evaluated the ef-
fects of baclofen on ethanol consumption using this paradigm in the
present study.
The mice from group A characterized in our model may have had
disproportional expression of the two subunits as a result of the
differential transcription levels found in the brain areas related to
drug taking and drug seeking, suggesting a possible explanation for
the lack of effect of baclofen in these mice. Even with baclofen treat-
ment, these mice maintained their high ethanol intake and higher
than the other two groups. From the phenotypic analysis, we inferred
that the GABA agonist is efﬁcient in reducing ethanol intake when the
GABAB1 and GABAB2 subunits are effectively balanced. Some authors
have demonstrated that conformational alteration of the GABAB1
subunit and subsequently conformational alteration of the entire
GABAB1–GABAB2 complex is necessary for effective activation of the
GABAB receptor (Morishita et al., 1990). Consequently, the precise
balance between the two subunits is necessary for the activation of
the receptor. One question is how this disproportional receptor sub-
type expression can support a basis for research on individualizing
treatment. The present study has limitations, but our data highlightthe importance for more studies to test this hypothesis because in
humans it is also observed different ethanol drinking patterns and
some medications are able to reduce ethanol intake only in some in-
dividuals (Johnson, 2010). Indeed, Muzyk et al. (2012) in the recent
systematic review proposed to test the baclofen effect on individuals
with different ethanol intake patterns.
Our model is based on the three-bottle free-choice paradigm, with
prolonged voluntary access to unsweetened ethanol solutions, where
initially high consumption is alternated with days of near abstinence
probably because mice are experiencing the pharmacological effects of
the drug. During this acquisition phase, mice differently develop a char-
acteristic pattern of consumption that remains stable for several weeks.
Furthermore, during the withdrawal phases, the high-drinkers mice
(groups A and H) might experience “anxiety”-related behaviors that
could induce unpleasant effects and when ethanol is presented again
its negative reinforcing properties may reduce anxiety (Koob and Le
Moal, 1997). Data analyzing “anxiety”-related behaviors are not shown
here, but we have already demonstrated the manifestation of these
behaviors during abstinence in other replications of the model (Correia
et al., 2009; Fachin-Scheit et al., 2006; Ribeiro et al., 2008). But, the
most important characteristic of our model, which is determinant for
the differentiation between groups A and H, is that quinine adulteration
of the ethanol solution maintained ethanol consumption in the group A,
but not in the groups H, suggesting that A mice seek ethanol despite the
less-palatable tasting of quinine.
A limitation of the present model is that we did not verify whether
group differences in drinking quinine adulterated ethanol are related
to a higher motivation for ethanol or simply to differences in the per-
ceived aversive qualities of quinine per se. However, some authors
have also demonstrated the aversiveness of similar doses of quinine.
For example, Hopf et al. (2010) showed that quinine taste preference,
determined by home-cage two-bottle choice between water and
water+quinine, had similar dose–response relationship in (1) rats
that underwent 3–4 months of intermittent, home-cage, two-bottle ac-
cess to 20% ethanol (v/v) or water, (2) animals with continuous access
to ethanol, and (3) age-matched, ethanol-naive controls. Also, they
showed a ceiling effect of reducing water intake in concentrations
above 0.01 g/L of quinine. Whitney and Harder (1994) have already
shown that quinine is aversive for mice at concentrations as low as
10 μM. Lesscher et al. (2010) demonstrated that when C57BL/6J mice,
naturally high consumers, were exposed to limited access to ethanol
solutions during a period of 8 weeks, they consumed an aversive,
quinine-containing (from 250 μM) ethanol solution despite the simul-
taneous availability of an unadulterated ethanol solution.
Notably, each mouse consistently exhibits a persistent and charac-
teristic individual intake pattern (here demonstrated by three exam-
ples) allowing the classiﬁcation of mice into different groups. These
different intake patterns could reﬂect differences in the vulnerability
to the effects of ethanol, strengthening the relevance of the proposed
model since one of the most prominent characteristics seen in
humans is the great variability in the individual susceptibility to the
development of dependence. In addition, this approach would allow
the assessment of individualized treatment, which is a current ten-
dency nowadays mainly for humans (Johnson, 2010).
Additionally, the model incorporates a “natural” development
in the progression from initiation to “loss of control” of ethanol
consumption (Sanchis-Segura and Spanagel, 2006), which is ob-
served only in some individuals. We previously demonstrated the
model's reliability, which was replicated 10 times, and the same
proportions of mice that exhibited the differential intake proﬁles
were always found (about 18 to 25% are group A; 18 to 30% are
group H and 28 to 35% are group L). The model has proven face
validity, and also, has predictive validity when tested with naltrex-
one as a pharmacological challenge (Camarini et al., 2011; Correia
et al., 2009; Fachin-Scheit et al., 2006; Ribeiro et al., 2008). Besides,
there is another beneﬁt of developing such model in mice when
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lower cost.
Furthermore, another limitation in drinking studies has been that
rodents, unlike humans, rarely consume ethanol to become intoxicat-
ed. Even those lines genetically selected for preference generally stop
drinking when their BEC reaches about 50 to 70 mg% (Murphy et al.,
1986). However, some genetically rodent lines under certain condi-
tions (Crabbe et al., 2009; Murphy et al., 2002; McBride and Li,
1998) voluntarily exceed BECs of 100 mg%, which is considered an in-
toxication level. In a similar study of our lab using the samemodel, we
determined BEC levels at the end of the model (the day after AD
phase). We observed that “loss of control” mice exhibited average
BEC above this limit, i.e. 113 mg% while the “heavy drinker” mice
showed 79 mg% and the “light drinker” mice showed 48 mg%. The
BEC levels were positively correlated with the ethanol consumption
presented at the end of the model (Ribeiro et al., 2012).
In the present study, we modiﬁed the procedure of one of the
phases compared with other studies previously performed in our
lab (Correia et al., 2009; Fachin-Scheit et al., 2006; Ribeiro et al.,
2008, 2010, 2012). During the withdrawal phase in the previous stud-
ies, we used 2 weeks of prolonged abstinence, but the “alcohol depri-
vation effect” (ADE) was not consistently seen. The ADE, which was
ﬁrst described by Sinclair and Senter (1967), deﬁned as the temporary
increase in voluntary ethanol intake that occurs in different animal
species after a period of ethanol abstinence, has been proposed to
model the compulsive, uncontrolled ethanol seeking and consuming
behaviors that characterize ethanol relapse in human alcoholics
(Boening et al., 2001; McBride et al., 2002). Some authors suggested
that the use of the ADE as a model of craving and/or relapse reﬂects
the motivation that promotes the subsequent consumption of ethanol
and can cause relapse based on the negative reinforcing properties of
ethanol. Similarly, humans exhibit anxiety, depressed mood, and irrita-
bility during the ethanol withdrawal syndrome (Koob and Le Moal,
1997, 2001; Koob, 2000; Spanagel, 2003). Wolffgramm et al. (2000),
using rats in a model similar to the present one, demonstrated that
the ADE was related more to controlled consumption than to addic-
tion. They reported that after several weeks of ethanol deprivation,
the controlled drinkers, those that had not lost control over intake,
consumed higher daily doses than before deprivation. In contrast,
the loss of control animals maintained their high consumption of
the drug. In the present study, we introduced multiple cycles of absti-
nence in an attempt to enhance “negative affect”. We found that all
mice exhibited signiﬁcantly increase in ethanol intake after the with-
drawal cycles compared with the AC phase (see Fig. 2, aW1, aW2,
and aW3 cycles in which the mice had access to ethanol after 4-day pe-
riods of withdrawal), suggesting the ADE. These ﬁndings suggest
that at least in chronically drinking mice, the ADE represents a situa-
tion of increased motivation to seek and drink ethanol, which is com-
patible with the operational deﬁnition of craving (Markou et al.,
1993). However, although we have observed the ADE in all groups
(A, H, and L) during the cycles of the withdrawal phase, in the period
of baclofen or saline treatment only group L showed a nonsigniﬁcant
(p=0.07) ADE, i.e. the controlled ones. This observation is in accor-
dance to that reported by Wolffgramm et al. (2000). Nevertheless,
groups A, H and L when under saline treatment returned to their in-
take proﬁle seen in AC phase conﬁrming the internal reliability of
the model.
Tanchuck et al. (2011) reported that 5.0 mg/kg baclofen decreased
binge ethanol consumption in mice but also tended to decrease
water intake and signiﬁcantly decreased operant sucrose self-
administration. In our study, baclofen had no effect on water con-
sumption or on the body weight gain during the period mice were
under baclofen treatment. Maybe baclofen did not interfere with con-
summatory behavior, as suggested by other authors (Anstrom et al.,
2003). Also, we can suggest that the baclofen effects observed in the
present study perhaps occurred through a speciﬁc reduction inethanol consumption rather than nonspeciﬁc sedative effects. This
suggestion is based on the effects of ﬁve different doses of baclofen
on locomotor activity tested in a naïve group of mice. From these
data we chose the two doses (1.25 and 2.5 mg/kg) which did not
change locomotor activity and the other dose (5.0 mg/kg) which
was able to reduce locomotion in the open ﬁeld test. The choice of
the highest dose was just to test whether the effect on ethanol
consumption was due to a depressant effect on its overall activity. If
the sedative effect of baclofen was responsible for the decrease in
consumption, then all animals (A, H and L) would have reduced con-
sumption under the inﬂuence of 5 mg/kg. But, in the addiction model
we demonstrated that only 1.25 mg/kg baclofen reduced ethanol in-
take in “light” and “heavy” drinkers but not in “addicted” and control
groups. Importantly, one can expect that if the reduction in ethanol
consumption induced by this dose was due to sedative effects, then,
the higher dose (5.0 mg/kg) would cause more prominent sedation
leading to higher reduction in ethanol consumption, which actually
was not observed. Thus, these ﬁndings altogether indicated that the
effect of 1.25 mg/kg baclofen was speciﬁc on ethanol consumption.
Tanchuck et al. (2011) also described that baclofen was effective in
reducing ethanol consumption up to 8 h after injection, i.e., this effect
disappeared 10 h after the injection, suggesting that the timing of the
baclofen injection and subsequent access to ethanol might be critical
in determining how this drug affects ethanol intake, which was also
proposed by other authors (Brebner et al., 2002; Moore et al., 2007;
Shoaib et al., 1998). In our study, we assessed ethanol consumption
for 90 min, 30 min after baclofen treatment (data not shown here),
and all groups showed minor changes in ethanol consumption after
this period, but after 24 h the baclofen effect in reducing ethanol in-
take was observed. In the present study, the signiﬁcant effect of the
lowest dose of baclofen on group L, and a minor effect on group H,
may suggest that mice of these two groups have consumed ethanol
because of its reinforcing effects while group A was hypothesized to
consume ethanol because of a “loss of control” in limiting intake, ren-
dering the reinforcing properties of ethanol less relevant and then,
abolishing the effects of baclofen. These observations were very sim-
ilar to what we had suggested in our previous validation study using
naltrexone when we found similar response proﬁle in the three
different groups (Fachin-Scheit et al., 2006). The importance of sev-
eral different neurochemical systems, including GABAergic and
opioidergic systems, modulating ethanol's reinforcing and rewarding
properties has been extensively studied (reviewed in Koob and Le
Moal, 2006). However, our explanations are only speculations requir-
ing more studies.
Some evidence that may support this hypothesis is that GABAB re-
ceptor expression is proven to be most highly concentrated in the
frontal cortex, hippocampus, and thalamus (Margeta-Mitrovic et al.,
1999; Princivalle et al., 2001). These regions are preferentially acti-
vated by cues paired with drug availability and use (Chang et al.,
1994; Childress et al., 1999; George et al., 2001; Grant et al., 1996;
Woodward et al., 1999). Activity within these regions may provide a
substrate for anticipatory behavioral states that precede actual drug
use, and these states are not dependent on the acute or reinforcing
actions of a drug. These neural mechanisms related to reinforcement
that sustain behavioral activation states may be required for the initi-
ation of responding for ethanol, natural reinforcers, and other drugs
of abuse and may be disrupted in “loss of control” animals. Thus,
the lack of effect of baclofen in group A mice raises the hypothesis
that baclofen does not effectively alleviate the compulsive drive to
use drugs that contributes to relapse and other drug-seeking states,
which has also been suggested by other authors for animals and
humans (Addolorato et al., 2002; Anstrom et al., 2003; Ling et al.,
1998; Callahan et al., 1997; Lacey et al., 1988; Zaleski et al., 2001).
In the present study, only the lowest dose of baclofen (1.25 mg/kg)
showed a signiﬁcant effect. Recent data indicate that only 2.5 mg/kg
dose of baclofen selectively reduces binge drinking using the scheduled
239G.R. Villas Boas et al. / Pharmacology, Biochemistry and Behavior 102 (2012) 233–240high ethanol consumption procedure in mice (Tanchuck et al., 2011).
However, in Tanchuck's study, mice have access to ethanol for a limited
time (4–10 h for only a few days) in a binge drinkingmodel. Also, Janak
and Gill (2003) showed that rats that received 1 mg/kg baclofen
reduced their ethanol self-administering, but 3 mg/kg had no effect.
Our results highlights the importance to study baclofen effect on
different ethanol intake proﬁles in animals and maybe also in humans
with different degrees of alcoholism.Acknowledgments
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